QN-023a / Qihan Biotech - LARVOL DELTA

Natural Killer(NK) Cell Therapy for Acute Myeloid Leukemia (clinicaltrials.gov) - P1 | N=3 | Terminated | Sponsor: Institute of Hematology & Blood Diseases Hospital, China | N=18 ➔ 3 | Recruiting ➔ Terminated; It did not reach the expected results of clinical trial

Enrollment change • Trial termination • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology • CD33

Natural Killer (NK) Cell Therapy Targeting CD33 in Acute Myeloid Leukemia (clinicaltrials.gov) - P1 | N=19 | Recruiting | Sponsor: Zhejiang University

New P1 trial • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology • CD33

Off-the-Shelf, Multiplexed-Engineered iPSC-Derived CD33 CAR-NK Cells for Treatment of Acute Myeloid Leukemia (ASH 2022) - "Immune cell therapy has become a cornerstone in cancer therapy. When administered in combination with daratumumab, QN-023a demonstrated superior ADCC compared to unmodified iPSC-derived NK cells against primary AML blasts from patients. Together, we have engineered iPSC-derived QN-023a NK cells as promising clinical drug candidates for treatment of AML."

IO biomarker • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology • Solid Tumor • Transplantation • CD33 • IL15 • NKG2D

Natural Killer(NK) Cell Therapy for Acute Myeloid Leukemia (clinicaltrials.gov) - P1 | N=18 | Recruiting | Sponsor: Institute of Hematology & Blood Diseases Hospital

New P1 trial • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology • CD33